What Happened

The FDA granted Aptitude its first 510(k) clearance for the next-generation Metrix COVID diagnostic, which delivers three-times greater sensitivity and 30% faster results than its original emergency use authorized test. The diagnostic is now cleared for over-the-counter and professional use in CLIA-waived settings, supported by BARDA.

Who Is Affected

Aptitude, a Goleta, California-based diagnostics maker, is directly affected as it transitions from EUA to full regulatory clearance. Their growing customer base will see continued product availability, while the company's expansion into RSV, strep, and STI tests impacts potential partners and vendors in the lab and manufacturing space.

Market Impact

The clearance strengthens Aptitude's position in the COVID-19 diagnostic market ahead of the EUA termination, with no expected disruptions. As they scale the Metrix platform and add new tests, they'll likely need:

• Lab informatics and data management tools
• Quality management systems for regulated manufacturing
• Manufacturing execution systems to support expanded production

What to Watch

Watch for FDA decisions on Aptitude's Metrix COVID/Flu test, currently under review, and progress on RSV, strep, and STI diagnostics in late-stage development. The company's ability to scale operations while maintaining compliance will be key as they expand their commercial footprint.

Related coverage

• FDA Grants 510(k) Clearance to Click Therapeutics' Motivista for Schizophrenia
• FDA approves AbbVie's Parkinson's drug Juvmo (tavapadon) developed from UVA research
• FDA approves Lilly's Jaypirca as first noncovalent BTK inhibitor for first-line CLL/SLL
• FDA approves Mirum's oral drug Atebrioz for rare disease FOP